Reuters logo
BRIEF-AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
October 10, 2017 / 12:19 PM / 11 days ago

BRIEF-AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology

Oct 10 (Reuters) - AbbVie Inc

* AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology

* AbbVie Inc - ‍AbbVie obtained an exclusive option to license up to three of Turnstone’s next-generation oncolytic viral immunotherapies​

* AbbVie Inc - ‍Abbvie has an option to obtain all global development and commercialization rights to Turnstone Biologics’ Ad-MG1-MAGEA3 therapy​

* AbbVie inc - ‍financial terms were not disclosed​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below